Patents Issued in December 14, 2021
  • Patent number: 11197872
    Abstract: The present disclosure relates to compounds and methods of eradicating cancer stem cells by combining inhibitors of oxidative metabolism and glycolytic metabolism. Also described are compounds and methods of identifying a combination of inhibitors of oxidative metabolism and glycolytic metabolism to treat cancer stem cells.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: December 14, 2021
    Assignee: LUNELLA BIOTECH, INC.
    Inventors: Michael P. Lisanti, Federica Sotgia
  • Patent number: 11197873
    Abstract: The present invention provides pharmaceutical compounds for the treatment of high-grade superficial bladder cancer in patent in need thereof. Further described are compositions of azolium salts for use in such treatment.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: December 14, 2021
    Assignees: The University of Akron, The Institute for Cancer Research
    Inventors: Wiley Jay Youngs, Philip H. Abbosh, Michael Lee Stromyer, Marie Renee Southerland, Uttam Satyal, David Joseph Weader
  • Patent number: 11197874
    Abstract: A method of preventing contact allergies includes using at least one amphoteric chelating agent which includes a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y)Bn]c?Dc with B being OH?, BO2? or H+, Y being a tetracarboxylate which can be protonated four times to form ethylenediaminetetraacetic acid, n being an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na+, c being an integer equal to 0, 1, 2 or 3 and c? being a relative number having the same absolute value as c. A device, a part of which includes the amphoteric chelating agent, is also described.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: December 14, 2021
    Assignee: PREVOR INTERNATIONAL
    Inventors: Joel Blomet, Laurence Mathieu, Marie-Claude Meyer
  • Patent number: 11197875
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: December 14, 2021
    Assignee: ABBOTT LABORATORIES
    Inventors: Rachael Buck, Geralyn O. Duska-McEwen, Joseph P. Schaller
  • Patent number: 11197876
    Abstract: The invention provides compositions and methods for treating asthma in a subject in need thereof comprising administering chemically synthesized secoisolaricirecinol diglucoside (SDG), and in particular, a racemic mixture of the SDG (LGM2605), stereoisomers thereof, metabolites thereof, and analogs thereof. Also provided are methods for treating or preventing ozone-induced damage in a subject in need thereof.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: December 14, 2021
    Assignees: THE TRUSIEES OF THE UNIVERSITY OF PENNSYLVANIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Melpo Christofidou-Solomidou, Angela Haczku
  • Patent number: 11197877
    Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: December 14, 2021
    Assignee: GLYCOMIMETICS. INC.
    Inventors: John L Magnani, John M Peterson, Arun K Sarkar, Yusuf U Vohra, Myung-Gi Baek
  • Patent number: 11197878
    Abstract: The present specification relates to an anti-inflammatory composition including a novel quercetin-based compound isolated from a post-fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and may be widely used in various areas related to anti-inflammation.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: December 14, 2021
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Yong-Deog Hong, Jeong-Kee Kim
  • Patent number: 11197879
    Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 treating inflammation, and treating symptoms of metabolic syndrome.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: December 14, 2021
    Assignees: INGREDIENTS BY NATURE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: Robert M. Brewster, John A. Manthey
  • Patent number: 11197880
    Abstract: Provided herein is a composition comprising eriocitrin, and uses thereof for managing pre-diabetes and diabetes. The composition may be useful for increasing GLP-1 levels.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: December 14, 2021
    Assignee: INGREDIENTS BY NATURE, LLC
    Inventors: Robert M. Brewster, Thais Cesar, Carolina Barbosa Ribeiro
  • Patent number: 11197881
    Abstract: A reactivation composition for activating or re-activating expression of a silenced X chromosome gene in a cell includes a non-cytotoxic histone deacetylase (HDAC) inhibitor. The reactivation composition includes the non-cytotoxic HDAC inhibitor and may further include a DNA methylation inhibitor. A method of activating or re-activating expression of a silenced X chromosome gene in a cell includes administering a reactivation composition including a non-cytotoxic HDAC inhibitor. The method of activating or re-activating expression of a silenced X chromosome gene may further includes administering a reactivation composition that includes a non-cytotoxic HDAC inhibitor and an inhibitor of DNA methylation.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: December 14, 2021
    Assignee: California Institute of Technology
    Inventors: Mitchell Guttman, Chun-Kan Chen
  • Patent number: 11197882
    Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: December 14, 2021
    Assignee: Emory University
    Inventors: George R. Painter, Gregory R. Bluemling, Michael G. Natchus, David Guthrie
  • Patent number: 11197883
    Abstract: Disclosed herein are UBAP2L targeting agents and use of such agents for the treatment of a neurodegenerative disorder. Further disclosed herein are methods of monitoring the progression of a neurodegenerative disorder and methods of determining the efficacy of a neurodegenerative disorder therapy.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: December 14, 2021
    Assignee: The Regents of the University of California
    Inventors: Eugene Yeo, Sebastian Markmiller, En-Ching Luo
  • Patent number: 11197884
    Abstract: Provided herein are methods, compounds, and compositions for modulating expression of at least one member of the Notch signaling pathway in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a respiratory disorder associated with excessive mucus production in an individual.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: December 14, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Tamar R. Grossman
  • Patent number: 11197885
    Abstract: Described herein are materials and methods useful for the treatment of neurodegenerative disorders and bone disorders, as well as healing wounds, in a subject. Materials described herein include polysaccharide digestive products resulting from the enzymatic hydrolysis of low acyl gellan gum. Also described herein are pharmaceutical compositions comprising one or more of such materials, and methods for their preparation and use.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: December 14, 2021
    Assignee: The University of Toledo
    Inventors: Joshua J. Park, Dong-Shik Kim
  • Patent number: 11197886
    Abstract: The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and/or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: December 14, 2021
    Assignee: FIDIA FARMACEUTICI S.p.A.
    Inventors: Laura Pilotto, Giovanni Gennari, Anna Maria Zanellato
  • Patent number: 11197887
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: December 14, 2021
    Assignee: TRICIDA, INC.
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Patent number: 11197888
    Abstract: The conjugation of luteinizing hormone-releasing hormone (LHRH) with activated cisplatin using a malonate linker gives rise to a new Platinum-LHRH conjugate that effectively targets tumor cells that express the LHRH receptor. The Pt-LHRH conjugate may be used in a method for killing or inhibiting the growth of a tumor cell, especially in late state, highly invasive and aggressive stage IV tumors and in reoccurring tumors.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: December 14, 2021
    Assignee: Eastern Kentucky University
    Inventors: Margaret Ndinguri, Lindsay Calderon
  • Patent number: 11197889
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: December 14, 2021
    Assignees: ABT Holding Company, Oregon Health & Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Patent number: 11197890
    Abstract: The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using CXC chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: December 14, 2021
    Assignee: New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Surgery
    Inventor: Franck Barrat
  • Patent number: 11197891
    Abstract: Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds. The compounds and cells can be used to treat a number of conditions, including infectious diseases, hyperproliferative disorders, inborn errors of metabolism, chronic immunometabolic diseases, autoimmune diseases, organ transplant rejection, inflammatory disorders, and chronic pain, among others.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: December 14, 2021
    Assignee: LANDOS BIOPHARMA, INC.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
  • Patent number: 11197892
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: December 14, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Patent number: 11197893
    Abstract: A pure platelet-rich plasma (P-PRP) composition as an alternative to conventional antibiotic treatment of subclinical mastitis caused by Gram-positive bacteria in bovine including five live platelets and leukocytes, an anticoagulant, and an activating substance.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: December 14, 2021
    Assignee: Universidad de Caldas
    Inventors: Alejandro Ceballos, Jorge U. Carmona
  • Patent number: 11197894
    Abstract: Compositions that include extracts from sources of immune modulators that include nanofraction immune modulator molecules (i.e., molecules having molecular weights of about 3,000 Da and less) are disclosed. These compositions may also include other immune modulators, such as transfer factor. Administration of compositions with extracts that include nanofraction immune modulator molecules modulates the cell-mediated immunity (e.g., down-regulates undesired T cell activity) of a subject to which such compositions are administered. When administered with transfer factor, the combination of nanofraction immune modulator molecules and transfer factor down-regulates undesired T cell activity while increasing, or up-regulating, T cell activity against pathogens and other undesirable entities, such as cancer cells and other aberrant or mutated cells. Assays and assay techniques for evaluating the immune modulation capabilities of various substances are also disclosed.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: December 14, 2021
    Assignee: 4Life Patents, LLC
    Inventors: David A. Lisonbee, Calvin W. McCausland, Richard H. Bennett, Brent M. Vaughan, Shane M. Lefler
  • Patent number: 11197895
    Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: December 14, 2021
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Takenao Chino, Yasufumi Kaneda
  • Patent number: 11197896
    Abstract: The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: December 14, 2021
    Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
    Inventor: Howard V. Raff
  • Patent number: 11197897
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: December 14, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Eric Pamer, Peter McKenney, Silvia Caballero
  • Patent number: 11197898
    Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: December 14, 2021
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Furqan Ali, Sivakumar Arumugam, Shaheen Majeed, Kirankumar Beede
  • Patent number: 11197899
    Abstract: The present invention relates to a composition comprising as antifungal active agent at least 2·1010 CFU of lactobacilli and a sulfur-containing compound for use as a first-line treatment for candidiasis and for recurrent candidiasis.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: December 14, 2021
    Assignee: NEXBIOME THERAPEUTICS
    Inventor: Adrien Nivoliez
  • Patent number: 11197900
    Abstract: A food composition is disclosed which comprises the acid-resistant bacterial strain Lactobacillus acetotolerans LE36. The L. acetotolerans LE36 strain has anti-inflammatory properties. The food composition can be further provided as a pharmaceutical composition.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: December 14, 2021
    Assignee: TAIWAN ENZYME VILLAGE CO. LTD.
    Inventors: Chia-Li Wei, Yu-Ting Wang, Tsung-Yi Li, Ya-Chen Huang, Po-Jen Cheng
  • Patent number: 11197901
    Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: December 14, 2021
    Assignee: GRAPE KING BIO LTD.
    Inventors: Chin-Chu Chen, Yen-Lien Chen, Shin-Wei Lin, Yen-Po Chen, Ci-Sian Wang, Yu-Hsin Hou, Yang-Tzu Shih, Ching-Wen Lin, Ya-Jyun Chen, Jia-Lin Jiang
  • Patent number: 11197902
    Abstract: Methods for treatment and compositions are provided for increasing the health of humans, livestock, and companion animals. More particularly, dietary supplements (also referred to as PPA (prebiotic, probiotic, antibodies) compositions) for treating humans, livestock, and companion animals, and methods for making and using them for treatment of various conditions are disclosed.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: December 14, 2021
    Assignee: IG Biosciences Corporation
    Inventors: Valentino Grant, Dayna J. Campbell, George D. Ranglin
  • Patent number: 11197903
    Abstract: The present invention relates to a composition containing a bean extract extracted by low-concentration, low-grade alcohol or fractions thereof. The composition exhibits excellent effects in improving blood circulation, improving obesity, and preventing diabetes, hyperlipidemia and the like, and exhibits the effects of alleviating or treating the symptoms of diabetes, hyperlipidemia, and the like. The present invention also relates to a method for improving blood circulation and vascular health.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: December 14, 2021
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Hyun Jung Shin, Jin Kwan Kim, Chae Wook Kim, Kyung Mi Joo, Yeon Su Jeong, Kyung Min Lim, Dae-Bang Seo, Yung Hyup Joo, Sang Jun Lee, Young-Ho Park
  • Patent number: 11197904
    Abstract: The present invention relates to the area of pharmaceutical compositions. More particularly, the present invention relates to a series of pharmaceutical compositions (PTM) containing phyto-polyphenols (P), clinical drugs with selective targets (T) and a metal ions (M) and the methods thereof for use in prevention and therapy of infectious diseases, neurodegenerative diseases, dementia, diabetes, obesity, metabolic syndromes, osteoporosis, cancers and/or chronic pain.
    Type: Grant
    Filed: January 20, 2019
    Date of Patent: December 14, 2021
    Assignees: Chung Shan Medical University
    Inventor: Shoei-Yn Lin-Shiau
  • Patent number: 11197905
    Abstract: A composition includes a target pharmaceutical or biological agent, a solution containing the target pharmaceutical or biological agent, and substrate that is soluble in the solution. The substrate is capable of being solidified via a solidification process and the solidification process causes the substrate to become physically or chemically cross-linked, vitrified, or crystallized. As a result of the solidification process, particles are formed. The target pharmaceutical or biological agent within the solution retains proper conformation to ultimately produce a desired effect.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: December 14, 2021
    Assignee: TissueGen, Inc.
    Inventors: Jennifer Seifert, Paul R. Sood, Brent B. Crow, Kevin D. Nelson, Nickolas B. Griffin, Alpeshkumar P. Patel, Paul A. Hubbard
  • Patent number: 11197906
    Abstract: The present disclosure relates to, among other things, compositions and methods for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain. One aspect of the present disclosure relates to a composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: December 14, 2021
    Assignees: On Target Therapeutics LLC, Trustees of Tufts College, Tufts Medical Center
    Inventors: Charles Cohen, Krishna Kumar, Alan S. Kopin, Benjamin N. Harwood, Venkata S. Raman, Pedram Hamrah
  • Patent number: 11197907
    Abstract: Cultures of Delftia bacteria are disclosed. Antimicrobial agents derived therefrom are also disclosed.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: December 14, 2021
    Assignees: Ministry of Health, State of Israel, Sami Shamoon College of Engineeing (R.A), Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Israel Nissan, Noa Lea Tejman-Yarden, Chaim Rubinovitz, Yakov Davidov, Galia Rahav, Ari Robinson, Yoram Shotland
  • Patent number: 11197908
    Abstract: Disclosed herein are peptoids and methods for attenuating inflammatory responses, and more particularly RAGE-associated inflammatory responses.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: December 14, 2021
    Assignees: The Board of Trustees of the University of Arkansas, University of South Carolina
    Inventors: Shannon Servoss, Melissa Moss, Lauren Wolf
  • Patent number: 11197909
    Abstract: The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 14, 2021
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, David Hughes, Martin Patrick Hughes, Navdeep B. Malkar, Balasingam Radhakrishnan, Anuradha Vaidya
  • Patent number: 11197910
    Abstract: The present invention relates to the use of phosphotidylserine or pathogenic sugar targeted therapeutics for the management and treatment of microbial infections, including Zika, Dengue, West Nile, Ebola, H1N1, enteroviruses, Leishmaniasis, Malaria and Coronaviruses SARS-COV.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: December 14, 2021
    Assignee: VITRUVIAE LLC
    Inventors: Mahiuddin Ahmed, Sonia Sequeira
  • Patent number: 11197911
    Abstract: The present invention provides for a novel peptide inhibitor and method for treating neurological disorders related to a hexanucleotide (GGGGCC) repeat expansion in the non-coding region of the C9ORF72 gene. Also disclosed are related compositions and kits for therapeutic use in the treatment of the pertinent diseases.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: December 14, 2021
    Assignee: The Chinese University of Hong Kong
    Inventors: Ho Yin Edwin Chan, Jacky Chi-Ki Ngo, Qian Zhang
  • Patent number: 11197912
    Abstract: Compositions for and methods of preventing, reversing or treating viral infection-induced organ failure provided. The compositions are also suitable for treating and/or preventing COVID-19 and influenza. The compositions and methods employ MG53, which can be in the form of recombinant human MG53. The MG53 may also be administered as a composition that expresses and releases MG53 after in vivo administration of said composition to a subject.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: December 14, 2021
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Jianjie Ma, Jacob S. Yount, Matthew A. Sermersheim, Adam D. Kenney, Xinyu Zhou, Bryan A. Whitson, Nahush A. Mokadam, Tao Tan, Chuanxi Cai
  • Patent number: 11197913
    Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: December 14, 2021
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Marc Chevrier, Kamyar Farahi, Newman Yeilding
  • Patent number: 11197914
    Abstract: The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Characterized by high enzymolysis stability, high biological activity and no adverse reaction, the polypeptide compounds are capable of reducing abnormal increase of triglycerides and total cholesterol in blood induced by diabetes mellitus and high fat diet, reducing liver enzyme level, reducing liver injury and fibrosis stage, and preventing or treating non-alcoholic fatty liver diseases (NAFLDs), hyperlipemia and arteriosclerosis.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: December 14, 2021
    Inventors: Xianxing Jiang, Rui Wang
  • Patent number: 11197915
    Abstract: CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 14, 2021
    Assignee: OPKO BIOLOGICS LTD.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Patent number: 11197916
    Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: December 14, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kurt Schnecker, Eva Haidweger, Peter Turecek
  • Patent number: 11197917
    Abstract: Formulations having a protein component, in which the protein contains one or more digestion-aiding proteins, and/or one or more immunoprotective proteins. The formulations may also contain a fat component, a carbohydrate component, and vitamins and minerals. These formulations can be used to provide nutritional support to a subject, either as dietary supplements or as a primary source of nutrition, such as for an infant formula.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 14, 2021
    Assignee: ByHeart, Inc.
    Inventors: Ron Belldegrun, Mia Funt
  • Patent number: 11197918
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neovascular disease, including a collagen and a 34-mer pigment epithelium derived factor (PEDF) peptide as an active ingredient, more specifically, the combined administration of the collagen type I and the 34-mer pigment epithelium derived factor peptide increases the short antiangiogenic activity cycle of the PEDF and extends the dosage range of the PEDF to solve the discomfort and the side effects accordingly due to the conventional frequent injections and thus it can be applied as a therapeutic agent for various neovascular diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: December 14, 2021
    Assignee: NexThera Co., Ltd.
    Inventors: Sea Gwang Park, Kug Hwan Roh, Hyun Woong Kim, Sung Jae Park
  • Patent number: 11197919
    Abstract: Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain targeted to HER2, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: December 14, 2021
    Assignee: City of Hope
    Inventors: Saul J. Priceman, Stephen J. Forman, Christine E. Brown
  • Patent number: 11197920
    Abstract: The present invention relates to particles, particularly virus-like particles (VLPs), comprising fusion polypeptides comprising selected repeat units derived from the repeating regions of Type I and Type II circumsporozoite proteins (CSP) of Plasmodium vivax (Pv), together with an amino acid sequence derived from the C-terminal PvCSP sequence. In some embodiments, the fusion polypeptide additionally comprises an amino acid sequence derived from the N-terminal PvCSP sequence and/or a surface antigen polypeptide derived from Hepatitis B virus (HBV-S). The invention also relates to nucleotide sequences coding for such fusion polypeptides, vectors and plasmids comprising such nucleotide sequences, and host cells comprising such vectors and plasmids. The invention additionally relates to compositions, particularly vaccine compositions, comprising the fusion polypeptides or VLPs for use as vaccines for the prevention of malaria.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: December 14, 2021
    Assignee: Oxford University Innovation Limited
    Inventor: Arturo Reyes-Sandoval
  • Patent number: 11197921
    Abstract: The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and/or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: December 14, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jitin Bajaj, Michael Albert Winters, Emily Wen, Jian He